Menu
Search
|

Menu

Close
X

Conatus Pharmaceuticals Inc CNAT.OQ (NASDAQ Stock Exchange Global Market)

5.15 USD
-0.02 (-0.39%)
As of Feb 23
chart
Previous Close 5.17
Open 5.16
Volume 59,895
3m Avg Volume 80,262
Today’s High 5.22
Today’s Low 5.02
52 Week High 9.40
52 Week Low 3.88
Shares Outstanding (mil) 30.01
Market Capitalization (mil) 154.53
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
27
FY16
1
FY15
0
EPS (USD)
FY17
-0.465
FY16
-1.309
FY15
-1.310
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
5.65
8.35
Price to Book (MRQ)
vs sector
4.94
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
41.46
15.84
LT Debt to Equity (MRQ)
vs sector
41.46
12.39
Return on Investment (TTM)
vs sector
-51.27
13.63
Return on Equity (TTM)
vs sector
-74.50
15.39

EXECUTIVE LEADERSHIP

David Hale
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Steven Mento
President, Chief Executive Officer, Director, Since 2017
Salary: $460,000.00
Bonus: --
Keith Marshall
Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Alfred Spada
Executive Vice President - Research & Development, Chief Scientific Officer, Since 2015
Salary: $325,579.00
Bonus: --
David Hagerty
Executive Vice President, Clinical Development, Since 2014
Salary: $94,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

16745 W Bernardo Dr Ste 200
SAN DIEGO   CA   92127-1906

Phone: +1858.3762600

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

SPONSORED STORIES